Archive for September, 2007
Laparoscopic-Assisted Resection for Colorectal Cancer
Pierre Guillou
David Jayne
REFERENCE: J Clin Oncol 25:3061-3068
PIERRE GUILLOU, St James’ Hospital, Leeds
COMMENT: DAVID JAYNE, St James’ Hospital, Leeds
Laparoscopic-assisted resection for colorectal cancer has proved just as effective as conventional open surgery, according to researchers in Leeds, England. Peter Goodwin went to meet the chief investigator, Pierre Guillou, to ask him about the CLASSIC study results published in the Journal of Clinical Oncology. David Jayne, also from St James Hospital, told Peter Goodwin about the learning curve associated with laparoscopic-assisted colorectal cancer resection, and reviewed current developments toward fully laparoscopic procedures now being introduced.
PIERRE GUILLOU, St James’ Hospital, Leeds
COMMENT: DAVID JAYNE, St James’ Hospital, Leeds
Laparoscopic-assisted resection for colorectal cancer has proved just as effective as conventional open surgery, according to researchers in Leeds, England. Peter Goodwin went to meet the chief investigator, Pierre Guillou, to ask him about the CLASSIC study results published in the Journal of Clinical Oncology. David Jayne, also from St James Hospital, told Peter Goodwin about the learning curve associated with laparoscopic-assisted colorectal cancer resection, and reviewed current developments toward fully laparoscopic procedures now being introduced.
Colistin Use Linked to Outbreak of Rare Hospital Infection
Ramon Guevara
REFERENCE: Abstract K-1942, 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, 2007
RAMON GUEVARA, Los Angeles County Department of Public Health
A report on a hospital outbreak involving a rare pathogen, which was presented at ICAAC, may have an important message for the whole field of infection control. Elizabethkingia Meningoseptica was found in a Los Angles hospital outbreak in 2006 and its emergence was linked to the use of colistin. So was this antibiotic selecting for the pathogen? Derek Thorne spoke with Ramon Guevara of Los Angeles County Department of Public Health.
RAMON GUEVARA, Los Angeles County Department of Public Health
A report on a hospital outbreak involving a rare pathogen, which was presented at ICAAC, may have an important message for the whole field of infection control. Elizabethkingia Meningoseptica was found in a Los Angles hospital outbreak in 2006 and its emergence was linked to the use of colistin. So was this antibiotic selecting for the pathogen? Derek Thorne spoke with Ramon Guevara of Los Angeles County Department of Public Health.
Which HIV Treatment is Best for Patients with HIV and Hepatitis C?
Juan Berenguer
REFERENCE: Abstract V-1385, 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, 2007
JUAN BERENGUER, Hospital Gregorio Marañón, Madrid
A retrospective study has thrown doubt on the theory that protease inhibitors (PIs) are a preferable antiretroviral treatment for patients co-infected with HIV and Hepatitis C virus. Previous research had suggested that PIs had a more beneficial effect on liver fibrosis than NNRTIs, but a study based at the Hospital Gregorio Marañón in Madrid has found the opposite. Derek Thorne discussed the data with Juan Berenguer.
JUAN BERENGUER, Hospital Gregorio Marañón, Madrid
A retrospective study has thrown doubt on the theory that protease inhibitors (PIs) are a preferable antiretroviral treatment for patients co-infected with HIV and Hepatitis C virus. Previous research had suggested that PIs had a more beneficial effect on liver fibrosis than NNRTIs, but a study based at the Hospital Gregorio Marañón in Madrid has found the opposite. Derek Thorne discussed the data with Juan Berenguer.
Broad Approach, Including Computer System, to Improve Hospital Hygiene
Yehuda Carmeli
REFERENCE: Abstract K-1373, 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, 2007
YEHUDA CARMELI, Tel-Aviv Medical Center
Hospitals can prevent significant numbers of infections by taking up a multi-faceted approach, including the use of a computer program to guide the isolation of patients. Derek Thorne spoke to Yehuda Carmeli of the Tel-Aviv Medical Center about his hospital’s experience.
YEHUDA CARMELI, Tel-Aviv Medical Center
Hospitals can prevent significant numbers of infections by taking up a multi-faceted approach, including the use of a computer program to guide the isolation of patients. Derek Thorne spoke to Yehuda Carmeli of the Tel-Aviv Medical Center about his hospital’s experience.
DUET 1 and 2 Trials: TMC 125 has Superior Virologic and Immunologic Response Rates
Pedro Cahn
REFERENCE: Abstract H-717, 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, 2007
PEDRO CAHN, Juan A. Fernández Hospital, Buenos Aires
Etravirine provides a chance to rescue patients who are failing non-nucleoside regimens according to 24-week pooled results of the DUET-1 and -2 studies. Nicola Solomon discussed these major trials with Pedro Cahn, of Juan A. Fernández Hospital in Buenos Aires.
PEDRO CAHN, Juan A. Fernández Hospital, Buenos Aires
Etravirine provides a chance to rescue patients who are failing non-nucleoside regimens according to 24-week pooled results of the DUET-1 and -2 studies. Nicola Solomon discussed these major trials with Pedro Cahn, of Juan A. Fernández Hospital in Buenos Aires.
Hospital Hand Hygiene Program Successfully Rolled Out
Lindsay Grayson
REFERENCE: Abstract K-1374, 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, 2007
LINDSAY GRAYSON, Austin Hospital, Victoria, Australia
A hand hygiene campaign implemented in six hospitals in Victoria, Australia has saved lives from MRSA, and saved twice as much money as it cost. Lindsay Grayson from Austin Hospital explained his data to Derek Thorne.
LINDSAY GRAYSON, Austin Hospital, Victoria, Australia
A hand hygiene campaign implemented in six hospitals in Victoria, Australia has saved lives from MRSA, and saved twice as much money as it cost. Lindsay Grayson from Austin Hospital explained his data to Derek Thorne.
BORIS: A. baumanni Highly Resistant β-Lactamase and Varying Susceptibility Patterns
Jennifer Lavrrar, Jane Hata, Jeanette Block
REFERENCE: Slide Session C2-1360, 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, 2007
JANE HATA, bioMéríeux Inc, Durham
Reports from the BORIS study call for ongoing surveillance of multi-drug resistant Acinetobacter Baumanii. Investigators found varying susceptibility and resistance patterns across the United States that highlight the organisms ability to adapt. Nicola Solomon spoke with Jane Hata of bioMéríeux.
JANE HATA, bioMéríeux Inc, Durham
Reports from the BORIS study call for ongoing surveillance of multi-drug resistant Acinetobacter Baumanii. Investigators found varying susceptibility and resistance patterns across the United States that highlight the organisms ability to adapt. Nicola Solomon spoke with Jane Hata of bioMéríeux.
Entecavir for Hepatitis B Linked to HIV Resistance
Moira McMahon
REFERENCE:47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, 2007
MOIRA MCMAHON, Johns Hopkins University, Baltimore
The hepatitis B drug entecavir appears to select for a drug resistant HIV mutation – and this has implications for patients infected with both viruses. Derek Thorne got the details from Moira McMahon from Johns Hopkins University in Baltimore. .
MOIRA MCMAHON, Johns Hopkins University, Baltimore
The hepatitis B drug entecavir appears to select for a drug resistant HIV mutation – and this has implications for patients infected with both viruses. Derek Thorne got the details from Moira McMahon from Johns Hopkins University in Baltimore. .
Monoclonal Antibody to Help Treat HIV?
Jeffrey Jacobson
REFERENCE:47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, 2007
JEFFREY JACOBSON, Drexel University College of Medicine, Philadelphia
Could a monoclonal antibody have a role to play in HIV treatment? Early data on the PRO 140 antibody, presented at ICAAC, show that it does give responses. Derek Thorne discussed this news approach with Jeffrey Jacobson of Drexel University College of Medicine, Philadelphia.
JEFFREY JACOBSON, Drexel University College of Medicine, Philadelphia
Could a monoclonal antibody have a role to play in HIV treatment? Early data on the PRO 140 antibody, presented at ICAAC, show that it does give responses. Derek Thorne discussed this news approach with Jeffrey Jacobson of Drexel University College of Medicine, Philadelphia.
Audio Journal of Medicine: Maraviroc for HIV: Responses at 48 Weeks">Audio Journal of Medicine: Maraviroc for HIV: Responses at 48 Weeks
Jacob Lalezari
REFERENCE:47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, 2007
JACOB LALEZARI, Quest Clinical Research, San Francisco
Maraviroc could be a useful new drug for the treatment of some HIV infections, according to Jacob Lalezari of Quest Clinical Research in San Francisco. He presented 48 week results from the MOTIVATE 1 study and Derek Thorne spoke to him at ICAAC in Chicago.
JACOB LALEZARI, Quest Clinical Research, San Francisco
Maraviroc could be a useful new drug for the treatment of some HIV infections, according to Jacob Lalezari of Quest Clinical Research in San Francisco. He presented 48 week results from the MOTIVATE 1 study and Derek Thorne spoke to him at ICAAC in Chicago.
Starting Antiretroviral Therapy Can Trigger Leprosy
Diana Lockwood
REFERENCE:47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, 2007
DIANA LOCKWOOD, London School of Hygiene and Tropical Medicine
ICAAC delegates heard that ‘hidden’ leprosy can be triggered in some patients who are receiving HIV antiretroviral therapy. So what might this mean for the countries that are rolling out this therapy to large numbers of people? Derek Thorne discussed the issue with Diana Lockwood of the London School of Hygiene and Tropical Medicine.
DIANA LOCKWOOD, London School of Hygiene and Tropical Medicine
ICAAC delegates heard that ‘hidden’ leprosy can be triggered in some patients who are receiving HIV antiretroviral therapy. So what might this mean for the countries that are rolling out this therapy to large numbers of people? Derek Thorne discussed the issue with Diana Lockwood of the London School of Hygiene and Tropical Medicine.
Audio Journal of Medicine: Bortezomib for Multiple Myeloma Can Cause Reactivation of Viruses">Audio Journal of Medicine: Bortezomib for Multiple Myeloma Can Cause Reactivation of Viruses
Georg Härter
REFERENCE:47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, 2007
GEORG HÄRTER, University Hospital, Ulm
For patients with multiple myeloma being treated with the proteasome inhibitor bortezomib, doctor’s should be wary of viral reactivation – and they should give antiviral prophylaxis in all cases. This finding was unveiled at ICAAC by Georg Härter from the University Hospital in Ulm, and he shared his data with Derek Thorne.
GEORG HÄRTER, University Hospital, Ulm
For patients with multiple myeloma being treated with the proteasome inhibitor bortezomib, doctor’s should be wary of viral reactivation – and they should give antiviral prophylaxis in all cases. This finding was unveiled at ICAAC by Georg Härter from the University Hospital in Ulm, and he shared his data with Derek Thorne.
Obesity, Car Travel, Climate Change: Linked?»
Phil Edwards, London School of Hyugiene and Tropical Medicine
LSHTM Audio News
Obesity Linked to Motor Transport And Climate Change
Peter Goodwin questions Phil Edwards of the London School of Hygiene and Tropical Medicine about "competition between stomachs and petrol tanks" discussed in a letter he and his colleague Ian Roberts have written to the medical magazine: The Lancet.Phil Edwards, London School of Hyugiene and Tropical Medicine
© 2008 Audio Medica - Medical Audio News Interviews & Podcasts. 
